Cure and The New York Academy of Sciences to Co-Host Forum on Science and Business of AI-Driven Drug Discovery

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
  • AI and pharma thought leaders to share insights on transformative role of AI in drug discovery and development for personalized medicine, rare diseases and more

NEW YORK, June 24, 2024 /PRNewswire/ — Cure.®, a healthcare innovation campus in New York City, and The New York Academy of Sciences, an organization committed to advancing science and technology for the benefit of society, today announced an exciting two-part science technology seminar: Science and Business of AI-Driven Drug Discovery and Deepfakes & Democracy in the Age of AI.

Thought leaders in artificial intelligence and biopharmaceuticals will share their insights on how AI and machine learning accelerate target identification, predict compound interactions, and optimize clinical trial designs. Attendees will gain valuable perspectives on the potential for AI to drive personalized medicine and tackle rare diseases, among other potential applications.

Event Details for Science and Business of AI-Driven Drug Discovery

Speakers:

  • Maria Luisa Pineda, PhD, Co-Founder and CEO of Envisagenics
  • Grant Mitchell, MD, MBA, Co-Founder and CEO of Every Cure
  • Andrea Califano, PhD, Chair, Department of Systems Biology, Columbia University and President, Chan Zuckerberg Biohub New York

Opening remarks will be made by Nicholas B. Dirks, PhD, President and CEO, The New York Academy of Sciences, and the seminar will be moderated by Seema Kumar, CEO of Cure.

“AI-driven drug discovery is poised to revolutionize the biopharmaceutical industry by enhancing drug development efficiency, accuracy, and cost-effectiveness,” said Nicholas B. Dirks, President and CEO of The New York Academy of Sciences. “These technological advancements promise to bring more effective treatments to patients faster, marking a significant milestone in modern medicine and public health.”

With only about 10 percent of drug candidates making it through a typical development time of 12 to 18 years, the ability of AI and ML tools to optimize discovery has become an area of intense interest. The influx of substantial financial commitments from private and public sectors drives new collaborations and innovations.

“Our goal is to showcase real world examples from biotech and life science leaders who are already using AI and ML tools to develop new products, transform clinical trials, and work with regulators,” said Cure CEO Seema Kumar. “They will share examples of how these tools are changing the trajectory of healthcare research today and transforming the landscape for a healthier tomorrow.”

Information for Deepfakes & Democracy in the Age of AI will be available soon.

About Cure.
Cure is a healthcare innovation campus in the heart of New York City that features laboratory and business facilities, a collaboration residency, office space and premium event venues, including an education center, conference center, and iconic rooftop facility, as well as tools, mentoring, networking, and other assistance to members of its ecosystem. Cure houses on-campus startups and established companies. Residents regularly create synergies and collaborative partnerships with peer organizations across the spectrum of healthcare, from academic or private to non-profit or government, and focus on diagnostic, device, drug or vaccine discovery, development and production as well as care delivery and public health. Cure also offers industry-leading event programming focused on critical health topics. Cure’s mission is to foster and accelerate advances in health. For more information, please visit wewillcure.com.

About The New York Academy of Sciences
The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science for the benefit of society. With more than 20,000 Members in 100 countries, the Academy advances scientific and technical knowledge, addresses global challenges with science-based solutions, and sponsors a wide variety of educational initiatives at all levels for STEM and STEM-related fields. The Academy hosts programs and publishes content in the life and physical sciences, the social sciences, nutrition, artificial intelligence, computer science, and sustainability. The Academy also provides professional and educational resources for researchers across all phases of their careers. Please visit us online at www.nyas.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cure-and-the-new-york-academy-of-sciences-to-co-host-forum-on-science-and-business-of-ai-driven-drug-discovery-302180739.html

SOURCE Cure

Staff

Recent Posts

NJ Rallies Investment Power, Leveraging Capital from Garden State Venture Partners to Drive MedTech and Maternal Health Innovation

GLASSBORO, N.J.--(BUSINESS WIRE)--Two transformative healthcare announcements this week mark a new era for New Jersey’s…

10 hours ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

AUSTIN, Texas--(BUSINESS WIRE)--Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships…

10 hours ago

Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

13 hours ago

HCA Healthcare Reports Second Quarter 2025 Results

Raises 2025 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results…

13 hours ago

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2024 Results

Q4 Fiscal 2024 Highlights1Revenue of $1.2 million, a 16.4% increase over Q3 2024Gross profit of…

13 hours ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),…

16 hours ago